Correlation Between Immunovant and Madrigal Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Immunovant and Madrigal Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immunovant and Madrigal Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Immunovant and Madrigal Pharmaceuticals, you can compare the effects of market volatilities on Immunovant and Madrigal Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immunovant with a short position of Madrigal Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immunovant and Madrigal Pharmaceuticals.

Diversification Opportunities for Immunovant and Madrigal Pharmaceuticals

-0.52

Correlation Coefficient

Immunovant  Madrigal Pharmaceuticals

Excellent diversification

The 3 months correlation between Immunovant and Madrigal is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding Immunovant and Madrigal Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Madrigal Pharmaceuticals and Immunovant is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immunovant are associated (or correlated) with Madrigal Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Madrigal Pharmaceuticals has no effect on the direction of Immunovant i.e., Immunovant and Madrigal Pharmaceuticals go up and down completely randomly.

Pair Corralation between Immunovant and Madrigal Pharmaceuticals

Given the investment horizon of 90 days Immunovant is expected to under-perform the Madrigal Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Immunovant is 1.27 times less risky than Madrigal Pharmaceuticals. The stock trades about -0.11 of its potential returns per unit of risk. The Madrigal Pharmaceuticals is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  31,162  in Madrigal Pharmaceuticals on December 30, 2024 and sell it today you would earn a total of  1,625  from holding Madrigal Pharmaceuticals or generate 5.21% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Immunovant  vs.  Madrigal Pharmaceuticals

Immunovant

Risk-Adjusted Performance

Very Weak

Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Madrigal Pharmaceuticals

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain technical and fundamental indicators, Madrigal Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Immunovant and Madrigal Pharmaceuticals

The main advantage of trading using opposite Immunovant and Madrigal Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immunovant position performs unexpectedly, Madrigal Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Madrigal Pharmaceuticals will offset losses from the drop in Madrigal Pharmaceuticals' long position.

The idea behind Immunovant and Madrigal Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.